Mirum (MIRM) Q2 2025 Earnings Call Transcript

Total revenue of $128M (up 64% YoY) and raised full‑year revenue guidance to $490M–$510M, reflecting strong commercial momentum. Livmarli U.S. net sales were $57M and international net sales $31M (including a $11M Takeda Japan order); bile acid portfolio contributed ~$40M. Operating expense was $133M (R&D $46M, SG&A $63M, cost of sales $23M), cash and investments totaled $322M (up $29M) and the company was operating cash‑flow positive for the quarter. Pipeline advances include IND clearance for MRM‑3379 (Fragile X Phase II planned by year‑end) and VISTAS PSC enrollment expected to complete this quarter with top‑line data targeted Q2 2026.

Analysis

Mirum’s quarter points to a transition from an R&D-led story to a commercial-growth one where clinical catalysts matter as value accelerants rather than sole makers of value. The combination of durable cash flow generation and >50% commercial cash margins materially lowers forced-dilution risk and lets management self-fund enrollment-heavy programs — which compresses timeline risk for VISTAS/VANTAGE/EXPAND but increases the company’s exposure to execution risk on commercial scale-up and reimbursement rather than financing risk.

Two important second-order effects are under-appreciated by consensus: (1) broader PFIC detection via routine genetic testing is likely to import a continuous, multi-year patient flow (not a one-time launch bump), benefiting diagnostics vendors and raising the probability of sustained volume growth; (2) reliance on large, lumpy partner orders (Takeda) injects quarter-to-quarter headline volatility that can mask underlying underlying demand trends and create temporary working capital swings; inventory and channel timing, not end-market demand, will likely drive the next few surprises.

Key downside vectors are regulatory/reimbursement tightening on label extensions (pruritus endpoints are subjective and payors can restrict coverage by genotype or age) and trial surprises in VISTAS or Fragile X that would remove optionality rapidly. Upside scenarios are straightforward: a narrower-than-modeled variance in VISTAS noise, or stronger-than-expected tablet adoption, can re-rate shares materially between now and the VISTAS readout (Q2 2026) because the company is already revenue-positive and can convert incremental sales to free cash flow at high margins.

Key Decisions for Investors

• Long equity (MIRM) — Buy a size that reflects idiosyncratic biotech risk (e.g., 1-2% NAV). Timeframe: 6–12 months to capture VISTAS readout and tablet adoption; R/R: asymmetric — limited near-term downside given cash runway but binary upside on positive PSC readout or quicker-than-expected EXPAND adoption. Use a hard stop of -30% to control clinical binary tail risk.
• Long-dated call spread (MIRM) — Buy the Jan 2027 call and sell a higher strike to finance premium (e.g., 18–24 month tenor). Timeframe: captures Phase II Fragile X initiation and VISTAS top-line (Q2 2026) while limiting premium decay. R/R: cap upside but reduces cash at risk vs outright calls; position size 0.5–1% NAV.
• Income/volatility harvest using covered calls (MIRM) — If already long stock, sell 1–3 month covered calls ahead of expected Takeda reorder windows to monetize elevated IV and lumpy revenue risk. Timeframe: roll monthly into data-runup; R/R: generates cash while retaining asymmetric upside to clinical readouts; be ready to buy back if calls get exercised into a pre-catalyst spike.
• Event hedge (MIRM) — Buy a small allocation of near-dated puts (3–6 month) as insurance into VISTAS readout if owning stock or calls. Timeframe: protect downside around the Q2 2026 data event; R/R: limited premium for outsized protection against a negative readout that could re-price the entire commercial optionality.